Abstract:Proteolysis-targeting chimeras (PROTACs) are essential bifunctional molecules that target proteins of interest (POIs) for degradation by cellular ubiquitination machinery. Despite significant progress made in understanding PROTACs' functions, their therapeutic potential remains largely untapped. As a result of the success of highly flexible, scalable, and low-cost mRNA therapies, as well as the advantages of the first generation of peptide PROTACs (p-PROTACs), we present for the first time an engineering mRNA PROTACs (m-PROTACs) strategy. This design combines von Hippel-Lindau (VHL) recruiting peptide encoding mRNA and POI-binding peptide encoding mRNA to form m-PROTAC and promote cellular POI degradation. We then performed proof-of-concept experiments using two m-PROTACs targeting two cancer-related proteins, estrogen receptor alpha and B-cell lymphoma-extra large protein. Our results demonstrated that m-PROTACs could successfully degrade the POIs in different cell lines and more effectively inhibit cell proliferation than the traditional p-PROTACs. Moreover, the in vivo experiment demonstrated that m-PROTAC led to significant tumor regression in the 4T1 mouse xenograft model. This finding highlights the enormous potential of m-PROTAC as a promising approach for targeted protein degradation therapy. We developed mRNA proteolysis-targeting chimeras (PROTACs), a novel type of PROTACs, which incorporate mRNAs encoding E3 ligase recruiting peptide ligand and protein of interest (POI)-binding peptide ligand to promote cellular POI degradation. For the first time, we demonstrated that the encoding peptide PROTACs could degrade POIs and inhibit cell proliferation more effectively than the traditional peptide PROTACs, indicating their tremendous potential for targeted protein degradation therapy. image

MicroRNA‐Triggered Programmable DNA‐Encoded Pre‐PROTACs for Cell‐Selective and Controlled Protein Degradation

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Engineering POLYTAC Nanoparticles for Bioorthogonal Click Reaction-Enforced Protein Degradation and Breast Cancer Therapy

DNA framework-engineered chimeras platform enables selectively targeted protein degradation

DNA-templated spatially controlled proteolysis targeting chimeras for CyclinD1-CDK4/6 complex protein degradation

Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy

Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation

Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors

Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy

Enzyme-catalyzed Activation of Pro-PROTAC for Cell-selective Protein Degradation

A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy

Mrna PROTACs: Engineering PROTACs for High‐efficiency Targeted Protein Degradation

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Stimuli‐Responsive PROTACs for Controlled Protein Degradation

Precise Modulation of Protein Degradation by Smart PROTACs

mRNA PROTACs: engineering PROTACs for high-efficiency targeted protein degradation

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Glutathione-Scavenging Nanoparticle-Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects

Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy.

Protocol for constructing tumor-targeting ANM-PROTACs for degradation of transcription factors

Smart PROTACs Enable Controllable Protein Degradation for Precision Cancer Therapy